Skip to content

For investors

Evolution

Exocure™ was incorporated in 2019 in the US as a medical biotechnology company, with seed investment of $1.1M from US, South Korea and Europe.

Equity investments from institutional and private investors have financed discovery, R&D and patent prosecution. Research has been performed at various European laboratories, with positive preclinical data reported. This has increased the patent portfolio, creating the opportunity to develop a wider array of exosome drug candidates to treat a number of otherwise incurable diseases.

In 2023, all Exocure Biosciences INC™ assets were transferred to Exocure™ Sweden AB, in order to further consolidate the proprietary technology within a European regulatory framework. This provides wider access to multiple research facilities and a more structured biotechnology business environment. An additional 5M SEK shareholder investment has recently been executed to prepare for the extensive development.

Technology achievements to date:

  • Invention of new biotechnology to treat cancer or severe inflammation, including inflammatory eye disease, cytokine storm, and to provide highly efficient next generation exosome cosmeceuticals.
  • Invention of efficient and proprietary loading of exosomes with complicated cargos (peptides, siRNA, proteins).
  • Surface engineering achieving specific cell targeting.
  • Identification of synergistic anti-inflammatory functions.
  • Completion of R&D of synthetic bacterial vesicles for cancer, resulting in high impact publication and patent filing.
  • Loading of “synthetic bacterial vesicles” with immuno-oncology molecules, further increasing potency.
  • Development of highly efficient proprietary exosome isolation methods for manufacturing.

Exocure™ innovative patents and exosome-delivery technology will ensure successful outcomes for patients and clinicians to develop advanced medicines to achieve progress in otherwise incurable diseases.

We thank you for your interest in this innovative biotechnology opportunity.
For further inquiries, please contact:

Exocure
[email protected]

Jan Lötvall, MD PhD, Professor and Founder
[email protected]

Mats Persson, Chairman of the Board, Co-Founder
[email protected]